Grifols (NASDAQ:GRFS) Stock Rating Lowered by Zacks Research

Grifols (NASDAQ:GRFS) was downgraded by investment analysts at Zacks Research from a “strong-buy” rating to a “hold” rating in a research report issued to clients and investors on Thursday,Zacks.com reports.

Other equities research analysts have also recently issued reports about the company. Weiss Ratings reiterated a “hold (c)” rating on shares of Grifols in a report on Wednesday, October 8th. Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating on shares of Grifols in a research note on Tuesday, August 5th. Finally, Wall Street Zen downgraded shares of Grifols from a “strong-buy” rating to a “buy” rating in a research report on Saturday, October 11th. One equities research analyst has rated the stock with a Buy rating and four have issued a Hold rating to the company. According to data from MarketBeat, the company has an average rating of “Hold” and a consensus price target of $10.30.

Grifols Trading Up 1.0%

Shares of Grifols stock traded up $0.08 on Thursday, hitting $8.44. 1,326,688 shares of the company traded hands, compared to its average volume of 889,538. The company has a current ratio of 2.64, a quick ratio of 0.95 and a debt-to-equity ratio of 1.20. The company has a market cap of $5.80 billion, a PE ratio of 40.19, a PEG ratio of 0.32 and a beta of 0.69. The stock’s 50 day moving average price is $9.61 and its 200-day moving average price is $9.22. Grifols has a 52 week low of $6.19 and a 52 week high of $11.14.

Institutional Trading of Grifols

Several hedge funds have recently modified their holdings of GRFS. Versant Capital Management Inc grew its position in shares of Grifols by 39.5% in the 3rd quarter. Versant Capital Management Inc now owns 5,598 shares of the biotechnology company’s stock worth $56,000 after buying an additional 1,584 shares during the last quarter. Peterson Wealth Services boosted its stake in Grifols by 385.8% in the third quarter. Peterson Wealth Services now owns 7,287 shares of the biotechnology company’s stock valued at $73,000 after acquiring an additional 5,787 shares in the last quarter. EverSource Wealth Advisors LLC boosted its stake in Grifols by 127.4% in the second quarter. EverSource Wealth Advisors LLC now owns 8,219 shares of the biotechnology company’s stock valued at $74,000 after acquiring an additional 4,604 shares in the last quarter. Ballentine Partners LLC purchased a new position in Grifols in the first quarter worth $77,000. Finally, PNC Financial Services Group Inc. increased its position in shares of Grifols by 109.8% during the third quarter. PNC Financial Services Group Inc. now owns 8,634 shares of the biotechnology company’s stock worth $86,000 after purchasing an additional 4,518 shares in the last quarter.

About Grifols

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand’s disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer’s disease.